Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00661180 · ClinicalTrials.gov registry record · Phase 2
Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec
A Phase 2 study of Chronic Myelogenous Leukemia, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 4
- Study locations
NCT00661180 is a Phase 2 study of Chronic Myelogenous Leukemia that has completed, run by Bayer. The registered enrollment target is 10 participants, below the 282-participant average among 29 other Chronic Myelogenous Leukemia trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT00661180, a Phase 2 study of Chronic Myelogenous Leukemia, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the anti-cancer activity and safety of Bay 43-006, in patients who have Chronic Myelogenous Leukemia that resisted to Gleevec treatment, one of the standard medication administered for these patients.
Conditions Studied
Interventions
- DRUG Nexavar (Sorafenib, BAY43-9006)
Study Locations (4)
Other
- - Lyon
- - Paris
- - Poitiers
Oregon
- - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2004-01 |
| Est. Completion | 2005-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00661180
The ClinicalTrials.gov registry entry for NCT00661180 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 282-participant average among 29 other Chronic Myelogenous Leukemia trials with a reported enrollment target (96% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Myelogenous Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Nexavar (Sorafenib, BAY43-9006) is the first listed.
NCT00661180 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Other, Oregon.
Frequently Asked Questions
What is clinical trial NCT00661180 about?
NCT00661180 is a clinical study titled "Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec". The purpose of this study is to evaluate the anti-cancer activity and safety of Bay 43-006, in patients who have Chronic Myelogenous Leukemia that resisted to Gleevec treatment, one of the standard medication administered for these patients.
What is the current status of trial NCT00661180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2004-01. Estimated completion is 2005-02.
What conditions does trial NCT00661180 study?
This clinical trial studies the following conditions: Chronic Myelogenous Leukemia.
What interventions are being tested in trial NCT00661180?
The interventions under investigation include: Nexavar (Sorafenib, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00661180?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00661180 being conducted?
This trial has 4 study locations across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelogenous Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
RECRUITING · Phase 2
-
Allo HSCT Using RIC and PTCy for Hematological Diseases
RECRUITING · Phase 2
-
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
ACTIVE NOT RECRUITING · Phase 2
-
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
ACTIVE NOT RECRUITING · Phase 2
-
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.